Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Geneesmiddel-gen-nutraceutische interacties van cannabidiol en tacrolimus

8 september 2026 bijgewerkt door: Michael Eadon, Indiana University

The information learned in these studies will help to inform doctors as to how to appropriately adjust doses of cannabidiol and tacrolimus in order to improve health outcomes and long-term treatment success for transplant recipients.

Studie Overzicht

Gedetailleerde beschrijving

The commercial availability of cannabidiol, or CBD oil, has increased in the United Stated and this supplement has the potential to cause a variety of drug-drug interactions, including in solid organ transplant recipients who receive tacrolimus to prevent rejection. Through a series of pharmacokinetic and pharmacodynamics assays, this proposal will identify gene-drug and drug-drug interactions (DDI), including those that place transplant recipients at risk for increased toxicity related to their immunosuppression. The information learned in these studies will help to inform practitioners as to whether cannabidiol needs to be avoided in transplant recipients and how to appropriately adjust doses of CBD and immunosuppression in order to improve health outcomes and long-term treatment success in this high-risk population.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

57

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46202
        • IU Health University Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 75 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Age 18-75
  • Are judged healthy enough to participate as determined by and decided from a pre-enrollment screening session that includes medical history and laboratory tests such as blood and urine tests, and electrocardiography (EKG).
  • Agree to refrain from taking any prescription medications, over-the-counter medications, and herbal, dietary, and alternative supplements that may interact with the metabolism of the study drugs at least 2 weeks prior to the start of the study and until study completion.
  • Are willing to commit the time requested for this study
  • Are willing to refrain from smoking or use of tobacco or marijuana for at least two weeks prior to and until the completion of the study (the entire study lasts for approximately 26 days).

Additional Criteria for the Healthy volunteer study:

• Have a GFR above 60 ml/min/1.73m2 with proteinuria less than 0.3 grams by urine protein to creatinine ratio or 24 hour urine collection

Additional Criteria for the CKD study:

  • Have either:
  • A GFR less than or equal to 60 ml/min/1.73m2 or
  • The presence of greater than 0.3 grams of proteinuria by urine protein to creatinine ratio or 24 hour urine collection, but less than 3.5 gm of nephrotic range proteinuria as hypoalbuminemia may impact protein binding.

Exclusion Criteria:

  • Unable to provide informed consent
  • Have history of intolerance, allergic reactions (e.g. rash) or other forms of hypersensitivities to any of the study medications (tacrolimus or cannabidiol);
  • Are currently taking sedative agents, including agents for insomnia
  • Are underweight (body mass index (BMI) less than 18.5) or overweight [body mass index (BMI) greater than 35]
  • Have a positive pregnancy serum or urine test obtained just prior to each study, or are breast feeding
  • Are night shift workers
  • Are on dialysis
  • Have compromised liver function as defined by pre-screening bilirubin, AST and ALT testing including any elevation of bilirubin or AST/ALT more than 2x the upper limit of normal.
  • Are not willing to refrain from smoking or use of marijuana for at least two weeks prior to and until the completion of the study
  • Have a Hgb < 10.0 g/dL
  • Have gastrointestinal (digestive) disorders such as persistent diarrhea or malabsorption that would interfere with the absorption of orally administered drugs
  • Have a history of or current seizure disorder
  • Are currently on immunosuppression or are immunosuppressed.
  • Are recipients of a current allograft (heart, kidney, pancreas, liver, intestine, lung, stem cell transplant).
  • Have baseline EKG readings that are abnormal that could place the patient at the high risk.
  • Have alcohol (more than 4 alcoholic drinks per day on a regular basis) or drug abuse, including opioids, or have used tobacco products or marijuana within the past three months, and are unwilling or unable to stop taking these medications two weeks prior to and during the entire study period
  • Have participated in a research study involving intensive blood sampling or have donated blood within the past two months
  • Had an unplanned hospitalization in the last 6 months or two or more unplanned hospitalizations in the last 2 years.
  • Are taking prescription medications, that may interfere with the metabolism of the study drugs (e.g., inhibitors or inducers of CYP3A4/5 or CYP2C19 or those that will displace protein binding of tacrolimus/cannabidiol). Interactions will be screened according to the Flockhart table.
  • Are taking over-the-counter medications, herbal or dietary supplements, and alternative medicines that may interfere with the metabolism of the study drugs (e.g., inhibitors or inducers of CYP3A4/5 or CYP2C19 or those that will displace protein binding of tacrolimus/cannabidiol) that the subject is unwilling or unable to stop over the course of the study. Interactions will be screened according to the Flockhart table.
  • Are students under supervision of any of the study investigators.
  • Cannot commit the time requested for this study.
  • Have a known CYP3A4 *22/*22 genotype

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ondersteunende zorg
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: CYP3A5-expressoren zonder chronische nierziekte

5 mg once

Andere namen:
  • Periode 1

Epidiolex 5 mg/kg

Andere namen:
  • Periode 2

Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period

Andere namen:
  • Periode 3
Actieve vergelijker: CYP3A5-non-expressers zonder chronische nierziekte

5 mg once

Andere namen:
  • Periode 1

Epidiolex 5 mg/kg

Andere namen:
  • Periode 2

Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period

Andere namen:
  • Periode 3
Actieve vergelijker: CYP3A5-expressoren met chronische nierziekte

5 mg once

Andere namen:
  • Periode 1

Epidiolex 5 mg/kg

Andere namen:
  • Periode 2

Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period

Andere namen:
  • Periode 3
Actieve vergelijker: CYP3A5-niet-expressoren met chronische nierziekte

5 mg once

Andere namen:
  • Periode 1

Epidiolex 5 mg/kg

Andere namen:
  • Periode 2

Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period

Andere namen:
  • Periode 3

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The AUC0-Infinity Ratio of Tacrolimus With Cannabidiol Divided by Tacrolimus Alone
Tijdsspanne: 27 days

The primary outcome is the AUC0-Infinity ratio of tacrolimus with cannabidiol divided by tacrolimus alone between CYP3A5 expressers and non-expressers in subjects with and without chronic kidney disease (CKD). Tacrolimus whole blood concentrations were measured at 0, 20, 40, and 60 minutes and 2, 4, 6, 12, 24, 48, and/or 72 hours.

27 days

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Cell Viability Ratio
Tijdsspanne: 27 days

The hypothesis tested is that cannabidiol will reduce immune cell proliferation between Period 1 and Period 3. There is no comparison between CYP3A5 expressor groups intended for this outcome measure. Period 1 (pre-CBD or baseline measurement) and Period 3 (post-CBD or steady-state cannabidiol) will be compared in a subset of individuals undergoing this phenotyping. Cell viability was measured in peripheral blood mononuclear cells using CellTiter-Glo (Promega Corp., catalog G7570) on 96-well plates to quantify cell proliferation by adenosine triphosphate (ATP) detection using a Spectramax M5 system coupled with SoftMax Pro 5.2 (Molecular Devices). Values were calculated as a unitless ratio of luminescence (ATP detection) in the stimulated (CD3/CD28) condition normalized by the non-stimulated (No CD3/CD28) condition.

27 days

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Michael Eadon, MD, Indiana University
  • Hoofdonderzoeker: Zeruesenay Desta, PhD, Indiana University

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

31 oktober 2022

Primaire voltooiing (Werkelijk)

31 augustus 2025

Studie voltooiing (Werkelijk)

31 augustus 2025

Studieregistratiedata

Eerst ingediend

3 augustus 2022

Eerst ingediend dat voldeed aan de QC-criteria

3 augustus 2022

Eerst geplaatst (Werkelijk)

5 augustus 2022

Updates van studierecords

Laatste update geplaatst (Werkelijk)

30 september 2026

Laatste update ingediend die voldeed aan QC-criteria

8 september 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren